Revised SPCs: Kalydeco (ivacaftor) granules in sachet- all strengths

Interactions with medicinal products edited to clarify that exposure to ivacaftor is significantly decreased by concomitant use of CYP3A inducers, and increased with exposure to strong or moderate CYP3A inhibitors. Further ADR data relating to transaminase elevations added.

Source:

electronic Medicines compendium